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ABSTRACT 
KatG is the gene in Mycobacterium tuberculosis which responsible for 
encoding of catalase peroxidase enzyme to enable its survival in host macrophage. 
KatG also reported to play an important role in enabling the killing effect of the anti-
tuberculous pro-drug, isoniazid (IN H). The mutation of this gene has been reported 
to create resistancy of Mycobacterium tuberculosis toward INH treatment. Since 
the killing effect of the drug has a significant relation with this gene, the structure 
and properties of KatG should be study for further information. 
EcoRI restriction enzyme was found to produce 2252 bp of DNA product. 
The gene was then sliced out from pCR®2.1-TOPO by using EcoRI restriction 
enzyme and ligated into a high-level protein expression vector, pRSET for 
expression assay. The recombinant sequenced has been confirmed by EcoRI-
Pvull restriction analysis. The gene has also been sequenced by cycle sequencing 




Tuberculosis (commonly shortened to TB) is an infectious disease which caused 
by infection with an acid fast bacilli named Mycobacterium tuberculosis. It is most 
commonly affects lungs (pulmonary TB) but can also affect the central nervous 
system (meningitis), lymphatic system, circulatory system (Miliary tuberculosis), 
genitourinary system, bones and joints. 
TB is a disease rich in paradoxes. It was one of the first disease for which the 
causative agent was identified, and one of the first for which a vaccine was 
developed (Calmette et.al., 1929 and Koch,R.,1982). Antibiotics effective against 
M.tuberculosis have been widely available for a half century (Iseman, et.a/., 2002). 
Yet it remains one of the great killer's infectious diseases in the world: HIV/AIDS 
kills 3 million people each year, TB kills 2 million, and malaria kills 1 million (WHO 
1998). 
Most recently, the human immunodeficiency virus (HIV) epidemic caused the 
number of new TB cases to explode (Aaron et.al., 2004). Multiple drug resistant 
.strains of TB (MDR-TB) are emerging. The World Health Organization declared TB 
a global health emergency in 1993. 
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1.1.1 History of tuberculosis 
Tuberculosis has been present in human since antiquity, as the origins of 
the diseases are in the first domestication of cattle. Tubercular decay has been 
found in the fragments of the spinal column from Egyptian mummies from 2400 
B.C (Mathew Sarrel). 
Around 460 BC Hippocrates identified "phthisis" (a Greek term for 
consumption) as the most widespread disease of the time which was almost 
always fatal. He even went so far as to warn other doctors not to visit patient in late 
stage of the disease due to the danger of catching it themselves. 
In the 17th century people began to describe and record the exact pathology 
of the disease. In 1679, Sylvius describe the actual tubercles as a characteristic 
change in the lungs and other parts of the body in consumptive patients in his 
publication named Opera Medica. He also described their progression to 
abscesses and cavities. 
In 1720, the English physician Benjamin Marten was the first to conjecture, 
in his publication, A New Theory of Consumption, which TB could be caused by 
"wonderfully minute living creatures", which, once they had gained a foothold in the 
body, could generate the lesions and symptoms of the disease. He stated, 
moreover, "It may be therefore very likely that by an habitual lying in the same bed 
with a consumptive patient, constantly eating and drinking with him, or by very 
frequently conversing so nearly as to draw in part of the breath he emits from the 
Lungs, a consumption may be caught by a sound person ... l imagine that slightly 
conversing with consumptive patients is seldom or never sufficient to catch the 
7 
disease." For the early eighteenth century, Dr. Marten's writings display a great 
degree of epidemiological insight. 
The bacillus-causing tuberculosis, Mycobacterium tuberculosis, was 
described on March 24, 1882 by Robert Koch. He received the Nobel Prize in 
physiology or medicine in 1905 for this discovery of a staining technique that 
enabled him to see Mycobacterium tuberculosis. 
The first genuine success in immunizing against tuberculosis developed 
from attenuated bovine strain tuberculosis by Albert Calmette and Camille Guerin 
in 1906 was BCG (Bacillus of Calmette and Guerin). It was first used on humans 
on July ·18, 1921 in France, although national arrogance prevented its widespread 
use in either the USA, Great Britain, or Germany until after World War II. 
In fact, the chemotherapy of infectious diseases, using sulfonamide and 
penicillin, had been underway for several years, but these molecules were 
ineffective against Mycobacterium tuberculosis. Since 1914, Selman A. Waksman 
had been systematically screening soil bacteria and fungi, and at the University of 
California in 1939 had discovered the marked inhibitory effect of certain fungi, 
especially actinomycete, on bacterial growth. In 1940, he and his team were able 
to isolate an effective anti-TB antibiotic, actinomycin; however, this proved to be 
too toxic for use in humans or animals. 
Success came in 1943. In test animals, streptomycin, purified from 
Streptomyces griseus, combined maximal inhibition of M. tuberculosis with 
relatively low toxicity. On November 20, 1944, the antibiotic was administered for 
the first time to a critically ill TB patient. The effect was almost immediately 
impressive. His advanced disease was visibly arrested, the bacteria disappeared 
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from his sputum, and he made a rapid recovery. The new drug had side effects -
especially on the inner ear- but the fact remained, M. tuberculosis was no longer a 
bacteriological exception, it could be assailed and beaten into retreat within the 
human body. 
A rapid succession of anti-TB drugs appeared in the following years. These 
were important because with streptomycin monotherapy, resistant mutants began 
to appear with a few months, endangering the success of antibiotic therapy. 
However, it was soon demonstrated that this problem could be overcome with the 
combination of two or three drugs. 
1.1.2 The bacterium 
The cause of tuberculosis, Mycobacterium tuberculosis (MTB), is a slow-
growing aerobic bacterium that divides every 16 to 20 hours. This is extremely slow 
compared to other bacteria, which tend to have division times measured in minutes 
(among the fastest growing bacteria is a strain of E. coli that can divide roughly 
every 20 minutes). It is not classified as either Gram-positive or Gram-negative 
because it does not have the chemical characteristics of either, although it contains 
peptidoglycan in their cell wall. If a Gram stain is performed, it stains very weakly 
Gram-positive or not at all. It is a small rod-like bacillus which can withstand weak 
disinfectants and can survive in a dry state for weeks but, spontaneously, can only 
grow within a host organism (in vitro culture of M. tuberculosis took a long time to 
be achieved, but is nowadays a normal laboratory procedure). 
MTB is identified microscopically by its staining characteristics: it retains 
certain stains after being treated with acidic solution, and is thus classified as an 
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"acid-fast bacillus" or "AFB". In the most common staining technique, the Ziehi-
Neelsen stain, AFB are stained a bright red which stands out clearly against a blue 
background. Acid-fast bacilli can also be visualized by fluorescent microscopy, and 
by auramine-rhodamine stain. 
The M. tuberculosis complex includes 3 other mycobacterium which can 
cause tuberculosis: M. bovis, M. africanum, and M. microti. The first two are very 
rare a cause of disease and the last one does not cause human disease. 
Nontuberculous mycobacteriums (NTM) is other mycobacterium (besides M. leprae 
which causes leprosy) which may cause pulmonary disease resembling TB, 
lymphadenitis, skin disease, or disseminated disease. These include 
Mycobacterium avium, M. kansasii , and others. 




TB is spread through aerosol droplets which are expelled when persons with 
active TB disease cough, sneeze, speak, or spit. Close contacts (people with 
prolonged, frequent, or intense contact) are at highest risk of becoming infected 
(typically 22 percent infection rate but everything is possible, even up to 100%). A 
person with untreated, active tuberculosis can infect an estimated 20 other people 
per year. Others at risk include foreign-born from areas where TB is common, 
residents and employees of high-risk congregate settings, health care workers who 
serve high-risk clients, medically underserved, low-income populations, high-risk 
racial or ethnic minority populations, children exposed to adults in high-risk 
categories, and people who inject illicit drugs. 
Transmission can only occur from people with active TB disease (not latent 
TB infection). 
The probability of transmission depends upon: infectiousness of the person 
with TB (quantity expelled), environment of exposure, duration of exposure, and 
virulence of the organism. 
The chain of transmission can be stopped by isolating patients with active 
disease and starting effective anti-tuberculous therapy. 
1.1.3.2 Infection 
TB infection begins when TB bacilli reach the pulmonary alveoli, and infect 
alveolar macrophages, where the mycobacterium replicates exponentially. Bacteria 
are picked up by dendritic cells, which can transport bacilli to local {mediastinal) 
I 1 
lymph nodes, and then through the bloodstream to the more distant tissues and 
organs where TB disease could potentially develop: lung apices, peripheral lymph 
nodes, kidneys, brain, and bone. 
Tuberculosis is classed as one of the granulomatous inflammatory 
conditions. Macrophages, T lymphocytes, 8 lymphocytes and fibroblasts are 
among the cells that aggregate to form a granuloma, with lymphocytes surrounding 
infected macrophages. The ~ranuloma functions not only to prevent dissemination 
of the mycobacteria, but also provides a local environment for communication of 
cells of the immune system. Within the granuloma, T lymphocytes secrete cytokine 
such as interferon gamma, which activates macrophages and make them better 
able to fight infection. T lymphocytes can also directly kill infected cells. 
Importantly, bacteria are not eliminated with the granuloma, but can become 
dormant, resulting in a latent infection. Latent infection can be diagnosed only by 
tuberculin skin test, which yields a delayed hypertype sensitivity response to 
purified protein derivatives of M. tuberculosis in an infected person. 
Another feature of the granulomas of human tuberculosis is the 
development of cell death, also called necrosis, in the center of tubercles. To the 
naked eye this has the texture of soft white cheese and was termed caseous 
necrosis. 
If TB bacteria gain entry to the blood stream from an area of tissue damage 
they spread through the body and set up myriad foci of infection, all appearing as 
tiny white tubercles in the tissues. This is called miliary tuberculosis and has a high 
case fatality. 
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In many patients the infection waxes and wanes. Tissue destruction and 
necrosis are balanced by healing and fibrosis. Affected tissue is replaced by 
scarring and cavities filled with cheese-like white necrotic material. During active 
disease, some of these cavities are in continuity with the air passages bronchi. 
This material may therefore be coughed up. It contains living bacteria and can pass 
on infection. 
Treatment with appropriate antibiotics kills bacteria and allows healing to take 
place. Affected areas are eventually replaced by scar tissue. 
1.2 KatG gene 
KatG gene is a gene that responsible to encode the catalase peroxidase 
enzyme in MTB which has 2223 bp in size (NG eta/., 2004). This heme-containing 
enzyme is part of a group of proteins known as hydroperoxidase I (HPI) or catalase 
peroxidase group (DeVito & Morris, 2002). The HPI protein is a bifunctional protein 
made out of catalase which turns hydrogen perixide into water and oxygen 
(2H202-+H20 + 02). Peroxidase on the other hand accepts protons to turn 
hydrogen peroxides into water (H202--+H20) (Haeym& Cole, 1997). 
The significance of katG was highlighted by Zhang eta/., when it was found 
that the deletion of this gene conferred isoniazid resistance, INHR to 
Mycobacterium tuberculosis (O'Brien et a/., 1995). Isoniazid (INH) was first 
reported to be effective against MTB in 1952 and has been playing a pivotal role in 
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the fight against TB since then (Quemard et a/., 1995). This drug is actually pro-
drug, and has been shown to be very effective against MTB with an MIC as low as 
0.021Jg/1JI (Haeym et a/., 1992). The function is essential in the use of present 
treatments against TB. Although used extensively, the exact mechanism of this 
drug has still eluded us. Studies by J.A. Ainsa eta/. (2001), and Wimpenny,(1967) 
that the katG gene activates the INH and reacted once again before it become a 
form toxic to MTB. This new toxic form will then bind to the NADH and the complex 
then inactivates inhA, a gene that share similar expression factor as katG. This is 
turn effects the action of the type II fatty acid synthase (FASII) impairing 
biosynthesis of mycolic acid and disrupts the cell wall production of the MTB (Ainsa 
eta/., 21001 ). 
1.3 Review of literature 
The usefulness of isoniazid (INH), a key component of short-course 
chemotherapy of tuberculosis, is threatened by the emergence of drug-resistant 
strains of Mycobacterium tuberculosis with mutations in the katG gene (Espinal et 
a/., 2001). The studies of Stover et a/., 2000 shows that resistance of M. 
tuberculosis to antimicrobial drugs is the consequence of spontaneous mutation in 
genes that encode either the target of the drug, or enzymes that are involved in 
drug activation. Heym et a/., 1994; and Zhang et a/., 2000 has described 
resistance-associated points mutation, deletions, or insertions for all first line drugs 
(isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin), and for several 
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second line and newer drugs (ethionamide, fluoroquinolones, macrolides, 
nitroimidazopyranes). 
Middlebrook et a/., 1954 has shown that isoniazid-resistant clinical isolates 
frequently lost its catalase and peroxidase activity. However, the association of this 
enzyme with isoniazid activation was not proven until the early 1990's, when the 
primary mycobacterial catalase-peroxydase gene (katG) was cloned and 
sequenced (Zhang eta/., 1992). Another study also has shown that mutation in this 
gene are found in 42- 58 % of isoniazid-resistant clinical isolates (Zhang et a/., 
2000; Ramaswamy eta/., 1998). 
Abal et a/.,2002 shows that 69% of the isoniazid-resistance from clinical 
isolates have mutation on katG gene where where Ser 315 is replaced by Thr 
(S315T) (Ahmad eta/., 2004). 
Due to these findings, it can be concluded that the structure of katG is an 
important determinant in finding the way on TB preventions. The isolation and 
expression of the katG gene is possible and has been performed. The molecular 
structure can be study now to expand the knowledge on the relationship of katG 
with isoniazid and the killing effect. 
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1.4 Objectives 
The main objective of this study is to characterize the katG gene by 
sequencing and restriction enzyme analysis. Since the sequence of katG has been 
known, the gene then ligated into the expression vector. The ligated katG into 
expression vector will later can be used to express the enzyme to study the protein 
structure by X-ray crystallography. 
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1.5 Flow chart of the study 
Figure 1.2: Flow chart of the study 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial Strains, culture and growth conditions 
One strain of Escherichia coli was employed in this study, which is listed in the 
Table 2.1. E. coli DH5a has been used to propagate and maintain of KatG1 and 
KatG7 (in pRSET B). Liquid and solid agar plate cultures were prepared according 
to the standard methods as published (Sambrook et.al). Bacteria were grown in the 
Luria-Bertani (LB) medium. The culture was maintained at 37°C. Cells were 
maintained for longer storage in the form of glycerol stocks and stored in -80°C. 
Table 2.1: Bacterial strain and its genotype used in this study 
Bacteria species 
· and strains ' 
E. coli DH5a. TM 
2.1.2 Plasmid 
Genotype _- : ·. :· :._: Supplier.. · 
F- cp80/acZ-aM 15 ll(/acZYA-argF)U 169 deoR 
recA1 endA1 hsdR17(rk-, mk+) phoAsupE44 Invitrogen, USA 
thi-1 gyrA96 re/A 1 'A-
There are two clones that have been specifically amplified by using PCR 
technique, which are known as KatG1 and KatG7. The amplified target has been 
cloned into pCR®2.1-TOPO plasmid vector and maintained in E.coli DH5a glycerol 
stock. The plasmid was designated as pKatG1 and pKatG7. These glycerol stocks 
were obtained from previous study (Eygene et.a/.,2005). The size of the gene is 
2252 base pair in size. 
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2.1.3 Expression vector 
The expression vector that has been used in this study is pRSET B. The map of 
vector is shown in Figure 2.1. 
RBS fATG. 









·version C docs not contain Sac I 
Figure 2.1: Map of pRSET A, 8, and C. 
(Adapted from https://www.invitrogen.com/content/sfs/manuals/prset_man.pdf) 
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